Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 8, 2006, Pages 685-689

  Tong, Yen ^a   Zhang, Ruhong ^a   Ngo, Suong N T ^a   Davey, Andrew K ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Fexofenadine; Isolated perfused liver; Organic anion transporting polypeptide; P glycoprotein; Rat

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FEXOFENADINE; GLYCOPROTEIN P; ORGANIC ANION TRANSPORTER; SODIUM CHLORIDE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG LIVER LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INJECTION; ISOLATED LIVER; LIVER PERFUSION; LIVER SINUSOID; MALE; NONHUMAN; RAT; RAT STRAIN;

ANIMALS; BILE; BILIARY TRACT; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE H1 ANTAGONISTS; INJECTIONS, INTRAPERITONEAL; KINETICS; LIPOPOLYSACCHARIDES; LIVER; MALE; METABOLIC CLEARANCE RATE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; TERFENADINE;

EID: 33745933294     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04419.x     Document Type: Article

References (26)

1. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab. Rev. 1997; 29: 1129-88.
2. Davey AK. Clinical relevance of cytokine-induced changes in drug metabolism. J. Pharm. Pract. Res. 2002; 32: 147-52.
3. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 2001; 42: 1007-17.
4. Ferenci P, Zollner G, Trauner M. Hepatic transport systems. J. Gastroenterol. Hepatol. 2002; 17 (Suppl.): S105-12.
5. Loo TW, Clarke DM. Nonylphenol ethoxylates, but not nonylphenol, are substrates of the human multidrug resistance P-glycoprotein. Biochem. Biophys. Res. Commun. 1998; 247: 478-80.
6. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin. Cancer Biol. 1997; 8: 161-70.
7. Dietrich CG, De Waart DR, Ottenhoff R, Schoots IG, Elferink R. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol. Pharmacol. 2001; 59: 974-80.
8. Walle UK, Walle T. Transport of the cooked-food mutagen 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) across the human intestinal Caco-2 cell monolayer: Role of efflux pumps. Carcinogenesis 1999; 20: 2153-7.
9. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002; 71: 537-92.
10. Kurelec B. A new type of hazardous chemical: The chemosensitizers of multixenobiotic resistance. Environ. Health Perspect. 1997; 105: 855-60.
11. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab. Dispos. 2004; 32: 20-7.
12. Bertilsson PM, Olsson P, Magnusson KE. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells. J. Pharm. Sci. 2001; 90: 638-46.
13. Goralski KB, Hartmann G, Piquette-Miller M, Renton KW. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br. J. Pharmacol. 2003; 139: 35-48.
14. Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos. 2004; 32: 734-41.
15. Piquette-Miller M, Pak A, Kim H, Anari R, Shahzamani A. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm. Res. 1998; 15: 706-11.
16. Sukhai M, Yong A, Kalitsky J, Piquette-Miller M. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b Genes. Mol. Cell Biol. Res. Commun. 2000; 4: 248-56.
17. Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 2002; 303: 273-81.
18. Fernandez C, Buyse M, German-Fattal M, Gimenez F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J. Pharm. Pharm. Sci. 2004; 7: 359-71.
19. Achira M, Totsuka R, Kume T. Decreased activity of hepatic P-glycoprotein in the isolated perfused liver of the adjuvant arthritis rat. Xenobiotica 2002; 32: 963-73.
20. Faber KN, Muller M, Jansen PL. Drug transport proteins in the liver. Adv. Drug Deliv. Rev. 2003; 55: 107-24.
21. Meijer D, van Montfoort J. Interactions of cationic drugs and cardiac glycosides at the hepatic uptake level: Studies in the rat in vivo, isolated perfused rat liver, isolated rat hepatocytes and oocytes expressing oatp2. Arch. Pharmacal Res. 2002; 25: 397-415.
22. Lee I-K, Lee Y-M, Song I-S et al. Hepatobiliary excretion of tributylmethylamonium in rats with lipopolysaccharide-induced acute inflammation. Arch. Pharmacol. Res. 2002; 25: 969-72.
23. Achira M, Totsuka R, Fujimura H, Kume T. Decreased hepatobiliary transport of methotrexate in adjuvant arthritis rats. Xenobiotica 2002; 32: 1151-60.
24. Milne RW, Larsen LA, Jorgensen KL, Bastlund J, Evans AM. Hepatic disposition of fexofenadine: Influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm. Res. 2000; 17: 1511-15.
25. Davey AK, Nicholls PJ. Toxicology of bacterial endotoxins. Toxic. Ecotoxic. News 1994; 1: 76-80.
26. Whiting JF, Green RM, Rosenbluth AB, Gollan JL. Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology 1995; 22: 1273-8.